Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
Healthcare
$5.32 +0.56%
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
52W Low $4.35High $9.57
Volume 1.39M
Average 1.82M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$38.31M
FY 2025 · Annual
Investing Cash Flow
-$560,000.00
FY 2025 · Annual
Financing Cash Flow
$56.10M
FY 2025 · Annual
-40.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Depreciation & Amortization | 232K | 778K | 1.28M | 990K | 845K |
| Deferred Income Tax | 11.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Change in Working Capital | (876K) | 71K | (378K) | 346K | 2.19M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 669K | (1.21M) | 45K | (185K) | 802K |
| Other Working Capital | (1.55M) | 1.28M | (378K) | 531K | 1.39M |
| Other Non-Cash Items | 76K | (15.78M) | (301K) | 21.51M | (6.98M) |
| Operating Cash Flow | (22.22M) | (31.42M) | (34.24M) | (27.02M) | (38.31M) |
| Capital Expenditures | (1.84M) | (1.3M) | (457K) | (16K) | (587K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 27K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 177K | 0 | 0 |
| Investing Cash Flow | (1.84M) | (1.3M) | (280K) | (16K) | (560K) |
| Debt Repayment | 0 | 19.91M | 0 | (9.17M) | 36.21M |
| Common Stock Issued | 71.34M | 0 | 0 | 101.76M | 19.89M |
| Common Stock Repurchased | 0 | 0 | (121K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 465K | 64K | 0 | 1.69M | 0 |
| Financing Cash Flow | 71.8M | 19.97M | (121K) | 94.28M | 56.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.75M | (12.74M) | (34.65M) | 67.24M | 17.23M |
| Free Cash Flow | (24.05M) | (32.72M) | (34.7M) | (27.04M) | (38.9M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$38.2M
+ D&A$845.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
+ Working Capital$2.2M
- Other Non-Cash-$7.0M
= Operating Cash Flow-$38.3M
- Capex-$587.0K
= Free Cash Flow-$38.9M
Analysis
FY2025 free cash flow is -$38.9M. FCF conversion is 101.9% of net income. Operating cash flow was -$38.3M, with capex of -$587.0K. The largest bridge item is Other Non-Cash at -$7.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 |
Does CADL generate free cash flow?
Candel Therapeutics, Inc. (CADL) generated -$38.90M of free cash flow in fiscal 2025.
How much operating cash flow does CADL produce?
Operating cash flow was -$38.31M, before capital expenditures of $587,000.00.
Continue the stock analysis
Jump to another research area for this company.